FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1298-1307 October 29, 1998 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Glaucoma is the leading cause of irreversible blindness in the world. It is estimated that by the year 2000, 66.8 million people will be affected, of whom 6.7 million will be blind in both eyes.¹ Glaucoma is an optic neuropathy in which the axons of the optic nerve die and the plates of lamina cribrosa collapse, leading to loss of optic-nerve tissue and excavation, or "cupping," of the ophthalmoscopically visible optic-nerve head. When sufficient axonal loss occurs, peripheral vision declines; loss of central vision occurs much later. Most forms of glaucoma are painless, and the loss of vision is insidious.

Diagnosis

. . . [Full Text of this Article]

Treatment

-Adrenergic–Antagonist Drugs

Prostaglandin Analogues

Adrenergic-Agonist Drugs

Carbonic Anhydrase Inhibitors

Cholinergic Agonists

Cannabinoids

New Drugs

Conclusions

Source Information

From the Glaucoma Service, Department of Ophthalmology, University of Iowa College of Medicine, 200 Hawkins Dr., Iowa City, IA 52242, where reprint requests should be addressed to Dr. Alward.

References

This article has been cited by other articles:

• Kwon, Y. H., Fingert, J. H., Kuehn, M. H., Alward, W. L.M. (2009). Primary Open-Angle Glaucoma. NEJM 360: 1113-1124 [Full Text]  
• Gonzalez, J. R., Baiza-Duran, L., Quintana-Hau, J., Tornero-Montano, R., Castaneda-Hernandez, G., Ortiz, M., Alarcon-Oceguera, F., Beltran-Loustaunau, M., Cortez-Gastelum, M., Garciduenas-Mejia, J., Gomez-Bastar, P., Jimenez-Roman, J., Korder-Ortega, V., Paczka-Zapata, J., Torres-Segura, M., Velasco-Gallegos, G. (2007). Comparison of the Stability, Efficacy, and Adverse Effect Profile of the Innovator 0.005% Latanoprost Ophthalmic Solution and a Novel Cyclodextrin-containing Formulation. J Clin Pharmacol 47: 121-126 [Abstract] [Full Text]  
• Pacher, P., Batkai, S., Kunos, G. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol. Rev. 58: 389-462 [Abstract] [Full Text]  
• Pekdemir, M, Yanturali, S, Karakus, G (2005). More than just an ocular solution. Emerg. Med. J. 22: 753-754 [Abstract] [Full Text]  
• Eagan, R. K., Varol, P. (2004). Case Study: Atropine Ophthalmic Administration Unmasking Undiagnosed Diabetic Gastroparesis. Clin. Diabetes 22: 139-140 [Full Text]  
• Kang, J. H, Pasquale, L. R, Willett, W. C, Rosner, B. A, Egan, K. M, Faberowski, N., Hankinson, S. E (2004). Dietary fat consumption and primary open-angle glaucoma. Am. J. Clin. Nutr. 79: 755-764 [Abstract] [Full Text]  
• Lee, D. J., Gomez-Marin, O., Lam, B. L., Zheng, D. D., Jane, D. M. (2004). Trends in Visual Acuity Impairment in US Adults: The 1986-1995 National Health Interview Survey. Arch Ophthalmol 122: 506-509 [Abstract] [Full Text]  
• Diestelhorst, M, Larsson, L-I (2004). A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 88: 199-203 [Abstract] [Full Text]  
• Husain, S., Kaddour-Djebbar, I., Abdel-Latif, A. A. (2002). Alterations in Arachidonic Acid Release and Phospholipase C-{beta}1 Expression in Glaucomatous Human Ciliary Muscle Cells. IOVS 43: 1127-1134 [Abstract] [Full Text]  
• Lentschener, C., Ghimouz, A., Bonnichon, P., Parc, C., Ozier, Y. (2002). Acute Postoperative Glaucoma After Nonocular Surgery Remains a Diagnostic Challenge. Anesth. Analg. 94: 1034-1035 [Abstract] [Full Text]  
• Zhang, W Y, Po, A L. W., Dua, H S, Azuara-Blanco, A (2001). Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85: 983-990 [Abstract] [Full Text]  
• Orzalesi, N., Rossetti, L., Invernizzi, T., Bottoli, A., Autelitano, A. (2000). Effect of Timolol, Latanoprost, and Dorzolamide on Circadian IOP in Glaucoma or Ocular Hypertension. IOVS 41: 2566-2573 [Abstract] [Full Text]  
• Bylund, D. B., Chacko, D. M. (1999). Characterization of {alpha}2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates. IOVS 40: 2299-2306 [Abstract] [Full Text]  
• Neufeld, A. H., Sawada, A., Becker, B. (1999). Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA 96: 9944-9948 [Abstract] [Full Text]